[PSMA-based theranostics for prostate cancer : From imaging to treatment]

Area of Science:

• Nuclear Medicine
• Oncology
• Radiochemistry

Background:

• Prostate-specific membrane antigen (PSMA) ligands are increasingly important in nuclear medicine theranostics for prostate cancer.
• Theranostic approaches combine diagnostic imaging with targeted radionuclide therapy.

Purpose of the Study:

• To highlight the value of theranostic concepts using radiolabeled PSMA ligands.
• To emphasize their utility in both diagnostic work-up and treatment of advanced prostate cancer.

Main Methods:

• Literature review summarizing currently available knowledge.
• Focus on PSMA-based positron emission tomography-computed tomography (PET/CT) and radioligand therapy.

Main Results:

• PSMA PET/CT demonstrates high sensitivity and specificity for prostate cancer imaging, especially in biochemical recurrence.
• Promising results are noted for staging primary prostate cancer and treatment monitoring.
• Radioligand therapy with alpha and beta emitters shows potential as a third-line treatment for metastatic disease.

Conclusions:

• Nuclear medicine theranostics are increasingly impacting prostate cancer diagnostics and treatment.
• PSMA-targeted approaches offer significant clinical benefits for managing advanced prostate cancer.